Home LiteratureArticle Details
PMID: 12433677 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade.

Blood ·Vol. 101 ·No. 7 ·2003-04-01 ·Pages 2886-93

Blaha P, Bigenzahn S, Koporc Z, Schmid M, Langer F, Selzer E, Bergmeister H, Wrba F, Kurtz J, Kiss C, Roth E, Muehlbacher F, Sykes M, Wekerle T

Abstract

We recently developed a murine protocol for the induction of allogeneic mixed chimerism and tolerance employing nonmyeloablative total body irradiation (TBI), standard-dose bone marrow transplantation (BMT), and costimulation blockade (cobl) with an anti-CD154 monoclonal antibody (mAb) plus CTLA4Ig. We now evaluated whether a short course (1 month) of immunosuppressive drugs, which would be ethically required in the clinical setting of organ transplantation to prevent graft loss in case tolerance is not achieved, interferes with tolerance induced with this regimen. Our results show that calcineurin inhibitors (cyclosporin A [CyA] or tacrolimus [FK]) inhibit development of long-term chimerism and abrogate tolerance induction in this model. Rapamycin (rapa), methylprednisolone (MP), FTY720, and mycophenolate mofetil (MMF), in contrast, have no negative effect on chimerism or tolerance development. Peripheral deletion of donor-reactive T cells, which usually occurs in the weeks following BMT in this model, is blocked by CyA and FK, but not by the other drugs tested. Furthermore, we found that the additional use of compatible immunosuppressive drugs (rapa plus MMF plus MP) allows the dose of TBI to be reduced, so that mixed chimerism and donor skin-graft acceptance can be achieved with 1 Gy using clinically feasible cell numbers. Thus, this protocol of BMT with costimulation blockade can be safely combined with a clinically tested immunosuppressive regimen to permit success with a lower dose of irradiation. These results should facilitate clinical application of this tolerance strategy.

MeSH Terms
Animals Antibodies, Monoclonal/pharmacology Antigens, Differentiation/immunology Bone Marrow Transplantation/methods Drug Therapy, Combination Female Immune Tolerance/drug effects Immunosuppressive Agents/pharmacology,therapeutic use Lymphocyte Activation/drug effects Lymphocyte Culture Test, Mixed Mice Mice, Inbred BALB C Mice, Inbred C57BL Radiation Dosage T-Lymphocytes/cytology,immunology Transplantation Chimera Transplantation, Homologous/immunology,methods Whole-Body Irradiation
Chemicals
Antibodies, Monoclonal Antigens, Differentiation Immunosuppressive Agents
Authors & Affiliations
14 authors, click to expand affiliations / ORCID
Blaha Peter
Division of Transplantation, Department of Surgery, Vienna General Hospital, University of Vienna, Austria.
Bigenzahn Sinda
Koporc Zvonimir
Schmid Maximilian
Langer Felix
Selzer Edgar
Bergmeister Helga
Wrba Friedrich
Kurtz Josef
Kiss Christopher
Roth Erich
Muehlbacher Ferdinand
Sykes Megan
Wekerle Thomas
Article Info
Journal
Blood
Abbr.
Blood
ISSN
0006-4971
Published
2003-04-01
Epub
2002-00-14
Pages
2886-93
Language
English
Region
United States
NLM ID
7603509
Subset
IM
Grants
NHLBI NIH HHS · R01 HL44-9915 · United States
Corrections
ErratumIn
-
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com